PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage "PICASSO"

Active, not recruiting

Phase 4 Results N/A

Update History

25 Dec '15
The description was updated.
New
It has been generally accepted that 'old age' and 'hypertension' may be risk factors not only for cerebral infarction but also for cerebral hemorrhage. Usually 40 to 60 percent of recurrent strokes after cerebral hemorrhage cases are cerebral infarction; and 5 to 10 percent of recurrent stroke after cerebral infarction cases are cerebral hemorrhage. Consequently, for the reasons described above, hemorrhagic side effects including cerebral hemorrhage have been a great concern, in the usage of antiplatelet agent or anticoagulant for the secondary prevention in the patients with cerebral infarction. It is reported that the occurrence of cerebral hemorrhage tends to increase in cases of accompanying lacunar infarction which occurs more frequently in Asians than in Westerners, or periventricular ischemic change which increasingly occurs with ageing. Accordingly, the point is that the occurrence of cerebral hemorrhage should be primarily considered in the treatment of cerebral infarction, along with the phenomenon of an ageing population both in Asian countries including Korea. Nevertheless, so far there has been no clinical research regarding secondary prevention of stroke, particularly considering the risk of occurrence of hemorrhage in cerebral infarction cases. However, according to a recent study, when phosphodiesterase inhibitors including Cilostazol are used independently, or in combination with aspirin, secondary prevention can be improved without increasing the occurrence of hemorrhagic side effects. Considering this, if it is proved that the agent, Cilostazol, could decrease the risk of occurrence of stoke, along with no significant increase in the risk of occurrence of hemorrhagic side effects, by selecting a patent group with a high risk of cerebral hemorrhage, the agent (Cilostazol) may be recognized as an unique antiplatelet agent applicable to old-aged patient with cerebral infarction who have a certain risk of cerebral hemorrhage. - High risk of cerebral hemorrhage is defined as presence of history of cerebral hemorrhage with appropriate neuroimage findings or presence of asymptomatic old cerebral hemorrhage findings(equal or more than 8mm) or multiple microbleeds on the GRE images. - 1600 ischemic stroke patients with high risk of cerebral hemorrhage will be recruited and they are randomized into four groups (cilostazol plus probucol, aspirin plus probucol, cilostazol and aspirin) by 2X2 factorial design. - IMT and ABI will be measured every year during follow-up period and the results will be compared with the baseline data. The change of IMT and ABI will be analyzed with the occurrence of cardiovascular events. - The study will finish at least 1 year after the recruit of 1600th patients. Until the finish, all patients will continuously take study medications and visit every 3months at the study site. - Brain MRI including FLAIR and GRE will be done at the final visits.
Old
It has been generally accepted that 'old age' and 'hypertension' may be risk factors not only for cerebral infarction but also for cerebral hemorrhage. Usually 40 to 60 percent of recurrent strokes after cerebral hemorrhage cases are cerebral infarction; and 5 to 10 percent of recurrent stroke after cerebral infarction cases are cerebral hemorrhage. Consequently, for the reasons described above, hemorrhagic side effects including cerebral hemorrhage have been a great concern, in the usage of antiplatelet agent or anticoagulant for the secondary prevention in the patients with cerebral infarction. It is reported that the occurrence of cerebral hemorrhage tends to increase in cases of accompanying lacunar infarction which occurs more frequently in Asians than in Westerners, or periventricular ischemic change which increasingly occurs with ageing. Accordingly, the point is that the occurrence of cerebral hemorrhage should be primarily considered in the treatment of cerebral infarction, along with the phenomenon of an ageing population both in Asian countries including Korea. Nevertheless, so far there has been no clinical research regarding secondary prevention of stroke, particularly considering the risk of occurrence of hemorrhage in cerebral infarction cases. However, according to a recent study, when phosphodiesterase inhibitors including Cilostazol are used independently, or in combination with aspirin, secondary prevention can be improved without increasing the occurrence of hemorrhagic side effects. Considering this, if it is proved that the agent, Cilostazol, could decrease the risk of occurrence of stoke, along with no significant increase in the risk of occurrence of hemorrhagic side effects, by selecting a patent group with a high risk of cerebral hemorrhage, the agent (Cilostazol) may be recognized as an unique antiplatelet agent applicable to old-aged patient with cerebral infarction who have a certain risk of cerebral hemorrhage. - High risk of cerebral hemorrhage is defined as presence of history of cerebral hemorrhage with appropriate neuroimage findings or presence of asymptomatic old cerebral hemorrhage findings(equal or more than 8mm) or multiple microbleeds on the GRE images. - 1600 ischemic stroke patients with high risk of cerebral hemorrhage will be recruited and they are randomized into four groups (cilostazol plus probucol, aspirin plus probucol, cilostazol and aspirin) by 2X2 factorial design. - IMT and ABI will be measured every year during follow-up period and the results will be compared with the baseline data. The change of IMT and ABI will be analyzed with the occurrence of cardiovascular events. - The study will finish at least 1 year after the recruit of 1600th patients. Until the finish, all patients will continuously take study medications and visit every 3months at the study site. - Brain MRI including FLAIR and GRE will be done at the final visits.
The eligibility criteria were updated.
New
Inclusion Criteria: - Patients with transient ischemic attack (TIA) or ischemic stroke within 180 days prior to screening - Adult aged 20 years or older - High risk of hemorrhagic stroke (history of intracranial hemorrhage or imaging evidence of previous intracranial hemorrhage) - Informed consent Exclusion Criteria: - Clinical diagnosis of myocardial infarction or coronary intervention within 4 weeks - Bleeding tendency - Pregnant or breast-feeding woman - Hemorrhagic stroke within 6 months - Patient who was taking antithrombotic medication other than aspirin and does not agree to change the previous medication - Severe cardiovascular disease such as cardiomyopathy or congestive heart failure - Life expectancy less than one year - Contraindication to long term aspirin use - Enrolled in other clinical trial within 30 days
Old
Inclusion Criteria: - Patients with transient ischemic attack (TIA) or ischemic stroke within 180 days prior to screening - Adult aged 20 years or older - High risk of hemorrhagic stroke (history of intracranial hemorrhage or imaging evidence of previous intracranial hemorrhage) - Informed consent Exclusion Criteria: - Clinical diagnosis of myocardial infarction or coronary intervention within 4 weeks - Bleeding tendency - Pregnant or breast-feeding woman - Hemorrhagic stroke within 6 months - Patient who was taking antithrombotic medication other than aspirin and does not agree to change the previous medication - Severe cardiovascular disease such as cardiomyopathy or congestive heart failure - Life expectancy less than one year - Contraindication to long term aspirin use - Enrolled in other clinical trial within 30 days
11 Oct '14
The description was updated.
New
It has been generally accepted that 'old age' and 'hypertension' may be risk factors not only for cerebral infarction but also for cerebral hemorrhage. Usually 40 to 60 percent of recurrent strokes after cerebral hemorrhage cases are cerebral infarction; and 5 to 10 percent of recurrent stroke after cerebral infarction cases are cerebral hemorrhage. Consequently, for the reasons described above, hemorrhagic side effects including cerebral hemorrhage have been a great concern, in the usage of antiplatelet agent or anticoagulant for the secondary prevention in the patients with cerebral infarction. It is reported that the occurrence of cerebral hemorrhage tends to increase in cases of accompanying lacunar infarction which occurs more frequently in Asians than in Westerners, or periventricular ischemic change which increasingly occurs with ageing. Accordingly, the point is that the occurrence of cerebral hemorrhage should be primarily considered in the treatment of cerebral infarction, along with the phenomenon of an ageing population both in Asian countries including Korea. Nevertheless, so far there has been no clinical research regarding secondary prevention of stroke, particularly considering the risk of occurrence of hemorrhage in cerebral infarction cases. However, according to a recent study, when phosphodiesterase inhibitors including Cilostazol are used independently, or in combination with aspirin, secondary prevention can be improved without increasing the occurrence of hemorrhagic side effects. Considering this, if it is proved that the agent, Cilostazol, could decrease the risk of occurrence of stoke, along with no significant increase in the risk of occurrence of hemorrhagic side effects, by selecting a patent group with a high risk of cerebral hemorrhage, the agent (Cilostazol) may be recognized as an unique antiplatelet agent applicable to old-aged patient with cerebral infarction who have a certain risk of cerebral hemorrhage. - High risk of cerebral hemorrhage is defined as presence of history of cerebral hemorrhage with appropriate neuroimage findings or presence of asymptomatic old cerebral hemorrhage findings(equal or more than 8mm) or multiple microbleeds on the GRE images. - 1600 ischemic stroke patients with high risk of cerebral hemorrhage will be recruited and they are randomized into four groups (cilostazol plus probucol, aspirin plus probucol, cilostazol and aspirin) by 2X2 factorial design. - IMT and ABI will be measured every year during follow-up period and the results will be compared with the baseline data. The change of IMT and ABI will be analyzed with the occurrence of cardiovascular events. - The study will finish at least 1 year after the recruit of 1600th patients. Until the finish, all patients will continuously take study medications and visit every 3months at the study site. - Brain MRI including FLAIR and GRE will be done at the final visits.
Old
It has been generally accepted that 'old age' and 'hypertension' may be risk factors not only for cerebral infarction but also for cerebral hemorrhage. Usually 40 to 60 percent of recurrent strokes after cerebral hemorrhage cases are cerebral infarction; and 5 to 10 percent of recurrent stroke after cerebral infarction cases are cerebral hemorrhage. Consequently, for the reasons described above, hemorrhagic side effects including cerebral hemorrhage have been a great concern, in the usage of antiplatelet agent or anticoagulant for the secondary prevention in the patients with cerebral infarction. It is reported that the occurrence of cerebral hemorrhage tends to increase in cases of accompanying lacunar infarction which occurs more frequently in Asians than in Westerners, or periventricular ischemic change which increasingly occurs with ageing. Accordingly, the point is that the occurrence of cerebral hemorrhage should be primarily considered in the treatment of cerebral infarction, along with the phenomenon of an ageing population both in Asian countries including Korea. Nevertheless, so far there has been no clinical research regarding secondary prevention of stroke, particularly considering the risk of occurrence of hemorrhage in cerebral infarction cases. However, according to a recent study, when phosphodiesterase inhibitors including Cilostazol are used independently, or in combination with aspirin, secondary prevention can be improved without increasing the occurrence of hemorrhagic side effects. Considering this, if it is proved that the agent, Cilostazol, could decrease the risk of occurrence of stoke, along with no significant increase in the risk of occurrence of hemorrhagic side effects, by selecting a patent group with a high risk of cerebral hemorrhage, the agent (Cilostazol) may be recognized as an unique antiplatelet agent applicable to old-aged patient with cerebral infarction who have a certain risk of cerebral hemorrhage. - High risk of cerebral hemorrhage is defined as presence of history of cerebral hemorrhage with appropriate neuroimage findings or presence of asymptomatic old intraparenchymal hemorrhage (more than 10mm) on the GRE images. - 1592 ischemic stroke patients with high risk of cerebral hemorrhage will be recruited and they are randomized into four groups (cilostazol plus probucol, aspirin plus probucol, cilostazol and aspirin) by 2X2 factorial design. - IMT and ABI will be measured every year during follow-up period and the results will be compared with the baseline data. The change of IMT and ABI will be analyzed with the occurrence of cardiovascular events. - The study will finish at least 1 year after the recruit of 1592th patients. Until the finish, all patients will continuously take study medications and visit every 3months at the study site. - Brain MRI including FLAIR and GRE will be done at the final visits.
The eligibility criteria were updated.
New
Inclusion Criteria: - Patients with transient ischemic attack (TIA) or ischemic stroke within 180 days prior to screening - Adult aged 20 years or older - High risk of hemorrhagic stroke (history of intracranial hemorrhage or imaging evidence of previous intracranial hemorrhage) - Informed consent Exclusion Criteria: - Clinical diagnosis of myocardial infarction or coronary intervention within 4 weeks - Bleeding tendency - Pregnant or breast-feeding woman - Hemorrhagic stroke within 6 months - Patient who was taking antithrombotic medication other than aspirin and does not agree to change the previous medication - Severe cardiovascular disease such as cardiomyopathy or congestive heart failure - Life expectancy less than one year - Contraindication to long term aspirin use - Enrolled in other clinical trial within 30 days
Old
Inclusion Criteria: - Clinical diagnosis of ischemic stroke within 120 days - Adult aged 20 years or older - High risk of hemorrhagic stroke (history of intracranial hemorrhage or imaging evidence of previous intracranial hemorrhage) - Informed consent Exclusion Criteria: - Clinical diagnosis of myocardial infarction or coronary intervention within 4 weeks - Bleeding tendency - Pregnant or breast-feeding woman - Hemorrhagic stroke within 6 months - Patient who was taking antithrombotic medication other than aspirin and does not agree to change the previous medication - Severe cardiovascular disease such as cardiomyopathy or congestive heart failure - Life expectancy less than one year - Contraindication to long term aspirin use - Enrolled in other clinical trial within 30 days
A location was updated in Hong Kong.
New
The overall status was removed for Queen Elizabeth Hospital.
A location was updated in Hong Kong.
New
The overall status was removed for United Christian Hospital.
A location was updated in Hong Kong.
New
The overall status was removed for Pamela Youde Nethersole Eastern Hospital.
A location was updated in Shatin, NT.
New
The overall status was removed for Prince of Wales Hospital.
A location was updated in Cheongju.
New
The overall status was removed for Chungbuk National University Hospital.
A location was updated in Cheonan.
New
The overall status was removed for Soonchunhyang University Cheonan Hospital.
A location was updated in Wonju.
New
The overall status was removed for Wonju Christian Hospital.
A location was updated in Gyeonggi-do.
New
The overall status was removed for Kwandong University College of Medicine Myongji Hospital.
A location was updated in Jinju.
New
The overall status was removed for Gyeongsang National University Hospital.
A location was updated in Ansan.
New
The overall status was removed for Korea University Ansan Hospital.
A location was updated in Bucheon.
New
The overall status was removed for Soonchunhyang University Bucheon Hospital.
A location was updated in Goyang.
New
The overall status was removed for Inje University Ilsan Paik Hospital.
A location was updated in Goyang-si.
New
The overall status was removed for National Health Insurance Corporation Ilsan Hoapital.
A location was updated in Guri.
New
The overall status was removed for Hanyang University Guri Hospital.
A location was updated in Seongnam-si.
New
The overall status was removed for Bundang Medical Center, CHA University.
A location was updated in Uijeongbu.
New
The overall status was removed for Uijeongbu St. Mary's Hospital.
A location was updated in Changwon.
New
The overall status was removed for Samsung changwon Medical Center.
A location was updated in Iksan.
New
The overall status was removed for Wonkwang University Hospital.
A location was updated in Jeonju-si.
New
The overall status was removed for Chonbuk National University Hospital.
A location was updated in Chuncheon.
New
The overall status was removed for Kangwon National University Hospital.
A location was updated in Changwon.
New
The overall status was removed for Chang Won Fatima hospital.
A location was updated in Goyang.
New
The overall status was removed for Dongguk University International Hospital.
A location was updated in Anyang.
New
The overall status was removed for Hallym University Sacred Heart Hospital.
A location was updated in Seongnam.
New
The overall status was removed for Seoul National University Bundang Hospital.
A location was updated in Suwon.
New
The overall status was removed for Ajou University Hospital.
A location was updated in Busan.
New
The overall status was removed for Kosin University Gospel Hospital.
A location was updated in Busan.
New
The overall status was removed for Dong-A University Hospital.
A location was updated in Busan.
New
The overall status was removed for Pusan National University Hospital.
A location was updated in Busan.
New
The overall status was removed for Inje University Pusan Paik Hospital.
A location was updated in Daegu.
New
The overall status was removed for Daegu Fatima Hospital.
A location was updated in Daegu.
New
The overall status was removed for Keimyung University Dongsan Center.
A location was updated in Daejon.
New
The overall status was removed for Eulji University Hospital.
A location was updated in Deagu.
New
The overall status was removed for Dongsan Medical Center.
A location was updated in Deagu.
New
The overall status was removed for Deagu Catholic University Hospital.
A location was updated in Deagu.
New
The overall status was removed for Yeungnam University Medical Center.
A location was updated in Deagu.
New
The overall status was removed for Kyungpook National University Hospital.
A location was updated in Deajeon.
New
The overall status was removed for Deajeon St.Mary's Hospital, The Catholic University of Korea.
A location was updated in Deajeon.
New
The overall status was removed for Chungnam National University Hospital.
A location was updated in GwangJu.
New
The overall status was removed for Chosun University Hospital.
A location was updated in Gwangju.
New
The overall status was removed for Chonnam National University Hospital.
A location was updated in Incheon.
New
The overall status was removed for Gachon University Gil Hoapital.
A location was updated in Inchon.
New
The overall status was removed for Inha University Hospital.
A location was updated in Pusan.
New
The overall status was removed for Wallace Memorial Baptist Hospital.
A location was updated in Seoul.
New
The overall status was removed for Eulji Hospital.
A location was updated in Seoul.
New
The overall status was removed for Kangdong Sacred Heart Hospital, Hallym University.
A location was updated in Seoul.
New
The overall status was removed for Soonchunhyang University Hospital.
A location was updated in Seoul.
New
The overall status was removed for Kangbuk Samsung Hospital.
A location was updated in Seoul.
New
The overall status was removed for Seoul St.Mary's Hospital.
A location was updated in Seoul.
New
The overall status was removed for Hanyang University Medical Center.
A location was updated in Seoul.
New
The overall status was removed for Asan Medical Center.
A location was updated in Seoul.
New
The overall status was removed for Konkuk Univ. Hospital.
A location was updated in Seoul.
New
The overall status was removed for St. Mary's Hospital.
A location was updated in Seoul.
New
The overall status was removed for Chung-Ang University Medical Center.
A location was updated in Seoul.
New
The overall status was removed for Seoul National University Hospital.
A location was updated in Seoul.
New
The overall status was removed for Seoul Medical Center.
A location was updated in Seoul.
New
The overall status was removed for Seoul National University Borame Hospital.
A location was updated in Seoul.
New
The overall status was removed for Ewha Womans University Medical Center.
A location was updated in Seoul.
New
The overall status was removed for Korea University Anam Hospital.
A location was updated in Seoul.
New
The overall status was removed for Kyung Hee University Medical Center.
A location was updated in Seoul.
New
The overall status was removed for Severance Hospital.
A location was updated in Seoul.
New
The overall status was removed for Inje University Sanggye Paik Hospital.
A location was updated in Seoul.
New
The overall status was removed for Gangnam Severance Hospital.
A location was updated in Seoul.
New
The overall status was removed for Hangang Sacred Heart Hospital.
A location was updated in Seoul.
New
The overall status was removed for National medical center.
A location was updated in Seoul.
New
The overall status was removed for Kangnam Sacred Heart Hospital, Hallym University College of Medicine.
A location was updated in Seoul.
New
The overall status was removed for Korea University Guro Hospital.
A location was updated in Ulsan.
New
The overall status was removed for Ulsan University Hospital.
A location was updated in Manila.
New
The overall status was removed for University of Santo Tomas.
A location was updated in Manila.
New
The overall status was removed for Manila Doctors Hospital.
A location was updated in Pasig.
New
The overall status was removed for The Medical City.
A location was updated in Quezon City.
New
The overall status was removed for St. Luke's Medical Center.
16 Jun '12
A location was updated in Bucheon.
New
The overall status was removed for Soonchunhyang University Bucheon Hospital.
A location was updated in Changwon.
New
The overall status was removed for Samsung changwon Medical Center.
A location was updated in Changwon.
New
The overall status was removed for Chang Won Fatima hospital.
A location was updated in Pusan.
New
The overall status was removed for Wallace Memorial Baptist Hospital.
A location was updated in Manila.
New
The overall status was removed for University of Santo Tomas.
A location was updated in Quezon City.
New
The overall status was removed for St. Luke's Medical Center.
2 Jun '12
A location was updated in Makati City.
New
The overall status was updated to "Withdrawn" at Makati Medical Center.